Exchange: NASDAQ·Updated 11:23 AM EDT
CADL logo

CADLCandel Therapeutics Inc

$9.86
$0.02
(0.20%)
Today
EarningsAug 13
Mkt Cap$723.91M
Vol267,385.00
News
all
press releases
CADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’
Candel Therapeutics announced the initiation of a Phase 3 trial evaluating lead therapy CAN-2409 in advanced non-small cell lung cancer patients.
Stocktwits
News Placeholder
More News
News Placeholder
CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is Bullish
Candel Therapeutics Phase 3 prostate cancer trial showed a higher disease-free survival rate.
Stocktwits
News Placeholder
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade
The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 148.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
News Placeholder
Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data
Candel Therapeutics presented positive phase 3 prostate cancer data showing improved disease-free survival, while analysts maintained bullish expectations on the stock.read more...
Benzinga
News Placeholder
CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data
The company reported that, after a median follow-up of 58 months, CAN-2409 delivered a statistically significant 39% improvement in prostate cancer-specific disease-free survival versus placebo.
Stocktwits
News Placeholder
CADL Retail Bulls See Buyout Potential As Key Cancer Data Catalyst Approaches
Candel Therapeutics is set to present data on Friday from its Phase 3 clinical trial of Aglatimagene in patients with localized, intermediate- to high-risk prostate cancer
Stocktwits
News Placeholder
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow
Candel Therapeutics generated investor buzz ahead of a key prostate cancer data readout, while its first-quarter loss came narrower than consensus estimates.
Stocktwits
News Placeholder
Candel Therapeutics (NASDAQ:CADL) Sets New 12-Month High - Here's What Happened
Candel Therapeutics (NASDAQ:CADL) Hits New 52-Week High - What's Next...
MarketBeat
News Placeholder
Candel Therapeutics (CADL) to Release Earnings on Tuesday
Candel Therapeutics (NASDAQ:CADL) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-candel-therapeutics-inc-stock...
MarketBeat
News Placeholder
Candel Therapeutics (NASDAQ:CADL) Stock Price Up 6.1% - Should You Buy?
Candel Therapeutics (NASDAQ:CADL) Trading 6.1% Higher - Here's Why...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.